Physician profile
Fidel J Martinez
NPI 1922452911
$1,481.89
in general payments reported to CMS, 2019-2025
16 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.74 · 2023: $669 · 2024: $419 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $315.02 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $189.05 | 2023-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $181.84 | 2023-2025 | |
| Pfizer INC. | $164.04 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $130.81 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2023-2025 | Wainua, Farxiga |
| Amgen INC. | $86.51 | 2023-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.15 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $53.69 | 2023 | |
| Abbott Laboratories | $42.10 | 2023-2024 | Cardiomems, Merlin@Home |
| Kiniksa Pharmaceuticals International, Plc | $39.87 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $30.37 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $27.67 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $24.77 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $24.65 | 2025 | Attruby |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.42 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fidel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.